Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 54.1% in March

Minerva Neurosciences, Inc. (NASDAQ:NERV) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 26,100 shares, a decrease of 54.1% from the February 28th total of 56,900 shares. Based on an average daily trading volume, of 42,400 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the company’s stock are short sold.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC raised its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. 34.56% of the stock is currently owned by institutional investors.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock remained flat at $1.81 during trading hours on Friday. The stock had a trading volume of 10,508 shares, compared to its average volume of 28,423. Minerva Neurosciences has a 12 month low of $1.42 and a 12 month high of $3.69. The stock has a market cap of $12.66 million, a P/E ratio of -4.11 and a beta of 0.10. The stock has a fifty day moving average of $1.93 and a 200 day moving average of $2.23.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. As a group, sell-side analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on NERV. HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, February 26th. StockNews.com assumed coverage on shares of Minerva Neurosciences in a research note on Wednesday. They issued a “sell” rating for the company.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.